SCHEDULE 13G: Nantahala Capital Management and Principals Disclose 9.99% Stake in Opus Genetics

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, have reported a beneficial ownership of 9.99% in Opus Genetics, Inc.'s common stock as of March 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed a Schedule 13G indicating their beneficial ownership in Opus Genetics, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 4,697,656 shares of Opus Genetics, Inc. Common Stock.
• This ownership represents 9.99% of the total outstanding shares of the class.
• The reported shares include 1,539,761 shares that can be acquired within sixty days through the exercise of warrants.
• Nantahala Capital Management, LLC is classified as an investment adviser, while Wilmot B. Harkey and Daniel Mack are identified as control persons.
• The Reporting Persons hold shared voting power and shared dispositive power over all 4,697,656 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not convey explicit positive or negative sentiment regarding the issuer's performance or outlook. The acquisition of a significant stake by an institutional investor could be viewed positively by the market, but the document itself is neutral in tone.

Positives

• A significant institutional investor, Nantahala Capital Management, LLC, has taken a substantial 9.99% stake in Opus Genetics, Inc., potentially signaling confidence in the company's prospects.
• The investment includes a portion of shares acquirable through warrants, indicating a long-term interest or a strategic entry point.

Negatives

• The document is a standard ownership disclosure and does not contain negative operational or financial news about Opus Genetics, Inc.

Risks

• The document itself does not detail specific risks related to Opus Genetics, Inc.'s operations or financial health, but rather discloses a significant ownership stake.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Taki Vasilakis, Chief Compliance Officer of Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack)

Industry Context

This filing is a routine disclosure of a significant ownership stake by an investment firm in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an investment decision within the biotechnology or pharmaceutical sector where Opus Genetics, Inc. likely operates.

Related Party Transactions

• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala Capital Management, LLC, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than five percent of the outstanding shares of common stock beneficially owned by Nantahala.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially the stock price, signaling confidence or strategic interest from a notable investment firm.
• Management: Awareness of a large institutional holder may influence strategic decisions or communication with the investment community.

Key Dates

Keywords

Opus Genetics, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Warrants, Institutional Ownership